On October 5, 2013, the 15th subject was treated in our ongoing study of MDMA-assisted psychotherapy for U.S. veterans, firefighters, and police officers with service-related PTSD. On October 3, the U.S. Drug Enforcement Administration approved the amended study protocol due to the addition of a 100 mg dose condition (along with 30 mg, 75 mg, and 125 mg). The protocol received approval from the Food and Drug Administration on October 6 (after passing the 30-day review period without comment from the FDA), and approval from the Institutional Review Board on August 28. There are currently over 450 people on the waiting list for this study for 11 more openings, highlighting the pressing public need for our research into more effective treatments for PTSD.
